Biocept Launches Liquid Biopsy Immuno-Oncology PD-L1 Test
Immuno-oncology therapy fights cancer by stimulating a patient's immune system to directly attack tumor cells or by enhancing anti-tumor responses to man-made immune system proteins. Patients with cancers expressing the PD-L1 protein are more likely to respond to certain immuno-oncology therapeutics and several PD-L1-related immuno-oncology therapies have received
"Immunotherapy is among today's most promising approaches to improving the outcomes of patients with cancer and shows even greater potential in the future as drugs currently in development come to market," said
"Determining PD-L1 status is required to qualify patients for certain immuno-oncology therapeutics and our test allows for the detection of this protein's expression through a simple blood test, rather than an invasive tissue biopsy," said
"The
About
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including without limitation statements as to our ability to improve the diagnosis and treatment of cancer, immunotherapy's ability to improve
the outcomes of patients with cancer, our ability to broaden our commercial liquid biopsy test offering and open new market opportunities, the ability of our PD-L1 protein expression test to improve treatments for patients with recurrent or progressive disease, the ability of our PD-L1 protein expression test to show PD-L1 expression missed by multiple tissue samples, our ability to obtain clinical validation for our test and the publication of study results, the ability of our PD-L1 protein expression test to track and monitor a patient's expression of PD-L1 on cancer cells without the need for invasive tissue sampling, our impact on diagnostic strategies and planned future offerings, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these
forward-looking statements, as these statements are subject to numerous risk factors as set forth in our
Logo - http://photos.prnewswire.com/prnh/20151013/276540LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/biocept-launches-liquid-biopsy-immuno-oncology-pd-l1-test-300276443.html
SOURCE
News Provided by Acquire Media